Therapeutics Company Beats Analyst Consensus Estimates

In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addressing the underlying causes of genetic disorders. $Stoke Therapeutics(STOK.US)$